BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo® (insulin glargine 300 Units/mL) Max SoloStar®, the highest capacity long-acting ...
Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...
PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...
The FDA approves Sanofi's (NASDAQ:SNY) Toujeo (insulin glargine 300 Units/mL) Max SoloStar. The product holds 900 Units of Toujeo and can deliver up to 160 Units in a single injection. The company ...
New Insulin in Prefilled Pen Gets FDA Nod Sanofi announced that the Food and Drug Administration (FDA) has approved once-daily Toujeo (insulin glargine [rDNA origin]) injection 300 U/mL to improve ...
The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...
In Photo: Prof. Helen Baron of The Keck School of Medicine in California discusses Type 2 Diabetes Mellitus: Perspectives on Current Insulin Therapy. Health-care company Sanofi-Aventis has announced ...
A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi ($SNY) announced the availability of the long-acting basal ...
Toujeo will be available in the Toujeo SoloSTAR ®, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback